{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"cidec-related-familial-partial-lipodystrophy","columns":[{"gene":"","key":"population-f6aa81b8864f64cd004c","label":"Lipodystrophy, familial partial, type 5","mondoId":"MONDO:0014098","onsetQualifier":null,"originColumnKey":"MONDO:0014098/OMIM:615238","originalViews":[{"key":"MONDO:0014098/OMIM:615238","label":"Lipodystrophy, familial partial, type 5","scopeLabel":"OMIM:615238","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["1824acdd0383a9123cc7031e2de82f92d815491927dbb797e4975ce15254eab2","230eed48e887abd6ad484867034019e39dd18fe209f72a411d231c2b7585caac","3a0b527c8abbbde49ccb5d0e525058a92136a6c598420a0c6f36d52201e8bdff","60952a92a121969b9b159b7c09a58395a0f379c3539db51c13efd6e4990b2508","6b8106ec8d443ee77e557f9e9da8caf207c4a6e4ea929daf8e373ed72f9cbe89","748108da0168d94c01c237dfd98f88ddc8e475ef8510f1ee6ba124048fc69cf9","76b2583b6442646c528a81d2789926bb903ea46af687e64649662cc4daa96c13","a377d45f95e2afdb26de26c6c257fec02e508a0cc33aaa2883b91a8660b0e3ff","bf39b5882a342a0d7d17bf2633ff396c38d166f1a6816866c4e993fa944f3214","c629cbfb7ad9710e87b7f638ec262b5fcffacfb20a20ce0558173a7cfcae1b5d","d207bd246d351186f306c765d8c3568c414e325cb44d4acf68e39f842900b548"],"recordQualifiers":{},"scopeLabel":"OMIM:615238","sourceIds":["OMIM:615238"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."},{"gene":"","key":"population-b8b280c1a6dfc54be7f9","label":"CIDEC-related familial partial lipodystrophy","mondoId":"MONDO:0014098","onsetQualifier":null,"originColumnKey":"MONDO:0014098/ORPHA:435651","originalViews":[{"key":"MONDO:0014098/ORPHA:435651","label":"CIDEC-related familial partial lipodystrophy","scopeLabel":"ORPHA:435651","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["042d9f654d491b6b324bdd520399440f81515a23f59b02a200f0f36e2e9e1a30","04ce6c60cb11c738c41b53aa5e82f695d10b477b3995c4b3f34aa0ebdff2fecf","181c4c279de81f0ab4c2beb9717fc4e7b76f8dc727a8fd399b77ecfa326766e8","2bcf6ffcdfa873851c14122f36b73699fae5571f0dbdfe432b4dd0d953f295a0","3d847c228c598a5c8091c32a71747f94a6a60c2838258aa2a843e28029e425bb","4d49d4614c6915bc58f0005ab4c9b5f2f49fb8412f5fbf0459ecd69e9276ab40","60f12f029cc6c091bdd7c883db911b035c55e5edec1ebb0b76644eeab5152ef6","88ccd37a5ec1950729f70f13f303072ba4596093e3f7ca1fc230f4239962fce0","a08a7c576f357ae17c1f37d10e3064c16cf79073156e24b3e36f4e40892ef6e4","b942a88f974250179e35b120bfe47febd2a083a9f24c07d7779ada94090ccd4a","c4c59efcf03a64a0d7dc7408c8a3e3f6a1033619b7c769577ebafa1894629c10","cca3dce615cd4f2280385e0b2985410f04fd19a29d985efae639422465a55891","d8f3035e62a4424966bcab2d9da1695de68a7b01d9ba65315ce9e5564e45a0d7","e457e9f106535e4431a061d006fae6dd36b19dfccbfbedf7fbd691bca996c518","e5ffd6498d675e965db6e9b12d532cdb4a88993f131c9aa786f147e7f8a1e816","f5b9a072172571db19d714630e91842b5962e06eba12946b3cfc9208721743f1"],"recordQualifiers":{},"scopeLabel":"ORPHA:435651","sourceIds":["ORPHA:435651"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-f6aa81b8864f64cd004c","population-b8b280c1a6dfc54be7f9"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0000956","HP:0008981","HP:0030685","HP:0003292","HP:0001953","HP:0030796","HP:0001397"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":11,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":27,"sourceGroups":{"orphanet":16,"published":11}},"features":[{"hpoId":"HP:0000956","label":"Acanthosis nigricans","primary":true},{"hpoId":"HP:0008981","label":"Calf muscle hypertrophy","primary":true},{"hpoId":"HP:0030685","label":"Decreased adiponectin level","primary":true},{"hpoId":"HP:0003292","label":"Decreased serum leptin","primary":true},{"hpoId":"HP:0001953","label":"Diabetic ketoacidosis","primary":true},{"hpoId":"HP:0030796","label":"Elevated circulating C-peptide concentration","primary":true},{"hpoId":"HP:0001397","label":"Hepatic steatosis","primary":true},{"hpoId":"HP:0002240","label":"Hepatomegaly","primary":false},{"hpoId":"HP:0000822","label":"Hypertension","primary":false},{"hpoId":"HP:0002155","label":"Hypertriglyceridemia","primary":false},{"hpoId":"HP:0000831","label":"Insulin-resistant diabetes mellitus","primary":false},{"hpoId":"HP:0000858","label":"Irregular menstruation","primary":false},{"hpoId":"HP:0009125","label":"Lipodystrophy","primary":false},{"hpoId":"HP:0000292","label":"Loss of facial adipose tissue","primary":false},{"hpoId":"HP:0009017","label":"Loss of gluteal subcutaneous adipose tissue","primary":false},{"hpoId":"HP:0003635","label":"Loss of subcutaneous adipose tissue in limbs","primary":false},{"hpoId":"HP:0000876","label":"Oligomenorrhea","primary":false},{"hpoId":"HP:0001733","label":"Pancreatitis","primary":false},{"hpoId":"HP:0000147","label":"Polycystic ovaries","primary":false},{"hpoId":"HP:0003712","label":"Skeletal muscle hypertrophy","primary":false}],"ledeHtml":"A rare, genetic lipodystrophy characterized by abnormal subcutaneous fat distribution, resulting in preservation of visceral, neck and axilliary fat and absence of lower limb and femorogluteal subcutaneous fat. Additional clinical features are acanthosis nigricans, insulin-resistant type II diabetes mellitus, dyslipidemia, and hypertension, leading to pancreatitis, hepatomegaly and hepatic steatosis.","mondoId":"MONDO:0014098","node":{"canonicalSlug":"cidec-related-familial-partial-lipodystrophy","comparisons":[],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"CIDEC-related familial partial lipodystrophy","originalSourceId":"ORPHA:435651","paragraphs":["A rare, genetic lipodystrophy characterized by abnormal subcutaneous fat distribution, resulting in preservation of visceral, neck and axilliary fat and absence of lower limb and femorogluteal subcutaneous fat. Additional clinical features are acanthosis nigricans, insulin-resistant type II diabetes mellitus, dyslipidemia, and hypertension, leading to pancreatitis, hepatomegaly and hepatic steatosis."],"rawAttribution":"ORPHA:435651","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-25T03:41:50Z","upstream":"ORPHA:435651","url":"https://rarediseases.info.nih.gov/diseases/13125"},"ownColumnKeys":["population-f6aa81b8864f64cd004c","population-b8b280c1a6dfc54be7f9"],"publication":"published","relationships":[{"kind":"parent","label":"familial partial lipodystrophy","mondoId":"MONDO:0020088","slug":"familial-partial-lipodystrophy"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"published"},"records":[{"frequencyKind":"range","key":"042d9f654d491b6b324bdd520399440f81515a23f59b02a200f0f36e2e9e1a30","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000956","is_excluded":false,"label":"Acanthosis nigricans","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"04ce6c60cb11c738c41b53aa5e82f695d10b477b3995c4b3f34aa0ebdff2fecf","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003292","is_excluded":false,"label":"Decreased serum leptin","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"181c4c279de81f0ab4c2beb9717fc4e7b76f8dc727a8fd399b77ecfa326766e8","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001733","is_excluded":false,"label":"Pancreatitis","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"1824acdd0383a9123cc7031e2de82f92d815491927dbb797e4975ce15254eab2","raw":{"aspect":"P","body_system":"digestive","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0002240","is_excluded":false,"label":"Hepatomegaly","onset_id":null,"reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"230eed48e887abd6ad484867034019e39dd18fe209f72a411d231c2b7585caac","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0030796","is_excluded":false,"label":"Elevated circulating C-peptide concentration","onset_id":null,"reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"2bcf6ffcdfa873851c14122f36b73699fae5571f0dbdfe432b4dd0d953f295a0","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040280","hpo_id":"HP:0003635","is_excluded":false,"label":"Loss of subcutaneous adipose tissue in limbs","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"3a0b527c8abbbde49ccb5d0e525058a92136a6c598420a0c6f36d52201e8bdff","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000858","is_excluded":false,"label":"Irregular menstruation","onset_id":null,"reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"3d847c228c598a5c8091c32a71747f94a6a60c2838258aa2a843e28029e425bb","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002155","is_excluded":false,"label":"Hypertriglyceridemia","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"4d49d4614c6915bc58f0005ab4c9b5f2f49fb8412f5fbf0459ecd69e9276ab40","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003712","is_excluded":false,"label":"Skeletal muscle hypertrophy","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"60952a92a121969b9b159b7c09a58395a0f379c3539db51c13efd6e4990b2508","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000822","is_excluded":false,"label":"Hypertension","onset_id":null,"reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"60f12f029cc6c091bdd7c883db911b035c55e5edec1ebb0b76644eeab5152ef6","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000876","is_excluded":false,"label":"Oligomenorrhea","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"6b8106ec8d443ee77e557f9e9da8caf207c4a6e4ea929daf8e373ed72f9cbe89","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0002155","is_excluded":false,"label":"Hypertriglyceridemia","onset_id":"HP:0011462","reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"748108da0168d94c01c237dfd98f88ddc8e475ef8510f1ee6ba124048fc69cf9","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0003292","is_excluded":false,"label":"Decreased serum leptin","onset_id":null,"reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"76b2583b6442646c528a81d2789926bb903ea46af687e64649662cc4daa96c13","raw":{"aspect":"P","body_system":"skin","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000956","is_excluded":false,"label":"Acanthosis nigricans","onset_id":null,"reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"88ccd37a5ec1950729f70f13f303072ba4596093e3f7ca1fc230f4239962fce0","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0030685","is_excluded":false,"label":"Decreased adiponectin level","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"a08a7c576f357ae17c1f37d10e3064c16cf79073156e24b3e36f4e40892ef6e4","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000831","is_excluded":false,"label":"Insulin-resistant diabetes mellitus","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"a377d45f95e2afdb26de26c6c257fec02e508a0cc33aaa2883b91a8660b0e3ff","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0030685","is_excluded":false,"label":"Decreased adiponectin level","onset_id":null,"reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"b942a88f974250179e35b120bfe47febd2a083a9f24c07d7779ada94090ccd4a","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001397","is_excluded":false,"label":"Hepatic steatosis","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"bf39b5882a342a0d7d17bf2633ff396c38d166f1a6816866c4e993fa944f3214","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0001953","is_excluded":false,"label":"Diabetic ketoacidosis","onset_id":null,"reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"c4c59efcf03a64a0d7dc7408c8a3e3f6a1033619b7c769577ebafa1894629c10","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0009017","is_excluded":false,"label":"Loss of gluteal subcutaneous adipose tissue","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"c629cbfb7ad9710e87b7f638ec262b5fcffacfb20a20ce0558173a7cfcae1b5d","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0001397","is_excluded":false,"label":"Hepatic steatosis","onset_id":null,"reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"cca3dce615cd4f2280385e0b2985410f04fd19a29d985efae639422465a55891","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0008981","is_excluded":false,"label":"Calf muscle hypertrophy","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"d207bd246d351186f306c765d8c3568c414e325cb44d4acf68e39f842900b548","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:615238","disease_name":"Lipodystrophy, familial partial, type 5","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0009125","is_excluded":false,"label":"Lipodystrophy","onset_id":null,"reference":"PMID:20049731","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"d8f3035e62a4424966bcab2d9da1695de68a7b01d9ba65315ce9e5564e45a0d7","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040280","hpo_id":"HP:0009125","is_excluded":false,"label":"Lipodystrophy","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"e457e9f106535e4431a061d006fae6dd36b19dfccbfbedf7fbd691bca996c518","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0000292","is_excluded":true,"label":"Loss of facial adipose tissue","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"e5ffd6498d675e965db6e9b12d532cdb4a88993f131c9aa786f147e7f8a1e816","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002240","is_excluded":false,"label":"Hepatomegaly","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"f5b9a072172571db19d714630e91842b5962e06eba12946b3cfc9208721743f1","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:435651","disease_name":"CIDEC-related familial partial lipodystrophy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000147","is_excluded":false,"label":"Polycystic ovaries","onset_id":null,"reference":"ORPHA:435651","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/13125\" rel=\"noreferrer\">GARD</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>ORPHA:435651</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>A rare, genetic lipodystrophy characterized by abnormal subcutaneous fat distribution, resulting in preservation of visceral, neck and axilliary fat and absence of lower limb and femorogluteal subcutaneous fat. Additional clinical features are acanthosis nigricans, insulin-resistant type II diabetes mellitus, dyslipidemia, and hypertension, leading to pancreatitis, hepatomegaly and hepatic steatosis.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/13125\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"cidec-related-familial-partial-lipodystrophy","sourceDocuments":[{"name":"GARD: CIDEC-related familial partial lipodystrophy","reviewed":null,"source_release":"2026-10-25T03:41:50Z","url":"https://rarediseases.info.nih.gov/diseases/13125"}],"sourceNote":"","synonyms":["CIDEC-related familial partial lipodystrophy","CIDEC-related FPLD","FPLD5","lipodystrophy, familial partial, type 5"],"takeawayHtml":"","title":"CIDEC-related familial partial lipodystrophy"},"schemaVersion":1}
